Prostate Cancer Market Growth, Size, Share and Forecast

Prostate Cancer pipeline therapeutics constitutes close to 538 molecules. Out of which approximately 448 molecules are developed by Companies and remaining by the Universities/Institutes. Global Markets Direct's latest report Prostate Cancer – Pipeline Review, H1 2016, outlays comprehensive information on the therapeutics under development for Prostate Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Browse full report with TOC@ https://marketreportscenter.com/reports/338300/prostate-cancer-pipeline-review-h1-2016

Prostate Cancer Prostate cancer is a form of cancer that affects men and starts off in the prostate gland. Prostate cancer usually occurs in older men. Symptoms include trouble urinating, decreased force in the stream of urine, blood in the urine, pain in the lower back, hips or thighs, bone pain and erectile dysfunction. Predisposing factors include age, family history and obesity. Treatment includes surgery, chemotherapy and radiation therapy. The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 18, 84, 83, 4, 220, 36 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 11, 8, 52 and 19 molecules, respectively.

Furthermore, this report also reviews of key players involved in therapeutic development for Prostate Cancer and features dormant and discontinued projects. Driven by data built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Prostate Cancer - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Prostate Cancer - Pipeline...